<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05616598</url>
  </required_header>
  <id_info>
    <org_study_id>RC 39-10-2022</org_study_id>
    <nct_id>NCT05616598</nct_id>
  </id_info>
  <brief_title>Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters</brief_title>
  <official_title>Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Benha University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Benha University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatitis C virus is commona viral infection. Direct-acting antiviral (DAA) oral drugs has&#xD;
      been used in treatment of HCVs. the effect of these drugs on male infertility is still under&#xD;
      investigation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Semen analysis will be done to male patients with HCV before and after treatment with DAA.&#xD;
      The included men will take therapy for 3 months and HCV RNA titter will be evaluated. changes&#xD;
      of seminal parameters will be recorded and analyzed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2022</start_date>
  <completion_date type="Actual">December 31, 2022</completion_date>
  <primary_completion_date type="Actual">November 25, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>DAA oral therapy for HCV.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment of HCV</measure>
    <time_frame>3 months</time_frame>
    <description>HCV titer by PCR is below detection level</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Male Infertility</condition>
  <condition>HCV</condition>
  <arm_group>
    <arm_group_label>Pateint group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Men with HCV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Men without HCV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir +daclatasvir+ simeprevir+Ribavirin</intervention_name>
    <description>Oral daily dose of Sofosbuvir +daclatasvir + simeprevir+ Ribavirin for 3 months</description>
    <arm_group_label>Pateint group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Men patients with HCV&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients with other hepatic disease, endocrinal disorder, malignancy, or urinary tract&#xD;
        infection.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Men patients with HCV</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Faculty of Medicine, Benha University</name>
      <address>
        <city>Al Qalyūbīyah</city>
        <state>Benha</state>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benha Faculty of Medecine</name>
      <address>
        <city>Banhā</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>November 1, 2022</study_first_submitted>
  <study_first_submitted_qc>November 7, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2022</study_first_posted>
  <last_update_submitted>February 6, 2023</last_update_submitted>
  <last_update_submitted_qc>February 6, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Benha University</investigator_affiliation>
    <investigator_full_name>Essam Mohamed El-sayed Akl</investigator_full_name>
    <investigator_title>Assistant Professor of Dermatology and Andrology</investigator_title>
  </responsible_party>
  <keyword>Semen</keyword>
  <keyword>DAA</keyword>
  <keyword>Male infertility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Male</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Simeprevir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

